Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
Sources: Gehrig SM, Ryall JG, Schertzer JD, Lynch GS
"We've had this program available for only about a month, but we're seeing a really nice encouraging uptake from our members that have enrolled," Cutler reports
These six-month REVEAL-1 results are an important milestone in our understanding of the potential durability and trajectory of post-GLP-1 weight and metabolic maintenance with Revita, said Dr Adarsh M Thaker, Assistant Clinical Professor, Medicine, David Geffen School of Medicine at UCLA
This case demonstrated how semaglutide has the potential to improve psoriasis outcomes involving both the cutaneous presentation and associated comorbidities such as cardiovascular risk
Neuropsychopharmacology 38 , 16851697 (2013)